Celldex Therapeutics’ (CLDX) Buy Rating Reiterated at HC Wainwright
MarketBeatHC Wainwright reissued a “buy” rating and set a $80.00 price objective on shares of Celldex Therapeutics in a research note on Monday.
HC Wainwright reissued a “buy” rating and set a $80.00 price objective on shares of Celldex Therapeutics in a research note on Monday.